The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2.
R. W. Joseph
No relevant relationships to disclose
P. Hwu
No relevant relationships to disclose
M. A. Davies
No relevant relationships to disclose
M. B. Atkins
No relevant relationships to disclose
R. J. Sullivan
No relevant relationships to disclose